- Records
- 19
- Recruiting
- 11
- Recruiting sites
- 613
- Countries
- 18
ClinicalTrials.gov registry snapshot / 2026-07-24Peptide trials,
Peptide trials,
without the maze.
Search every official registry record matched to 13 tracked peptide and next-generation weight-loss programs. Find current status, phase, enrollment, countries, US states, recruiting cities, postal areas, completion timing, and the direct NCT source.
268unique NCT records
13named programs
53countries represented
1,840recruiting cities
11registry result modules
Recruiting footprint by program
Study status is not drug rank.
Bar length shows registry-listed sites individually marked Recruiting. Larger programs can create larger counts. This does not compare efficacy, safety, approval odds, sponsor quality, or enrollment availability.
- Records
- 52
- Recruiting
- 10
- Recruiting sites
- 170
- Countries
- 7
- Records
- 37
- Recruiting
- 10
- Recruiting sites
- 73
- Countries
- 3
- Records
- 24
- Recruiting
- 10
- Recruiting sites
- 935
- Countries
- 28
- Records
- 27
- Recruiting
- 6
- Recruiting sites
- 1,581
- Countries
- 36
- Records
- 30
- Recruiting
- 5
- Recruiting sites
- 155
- Countries
- 6
- Records
- 8
- Recruiting
- 4
- Recruiting sites
- 339
- Countries
- 23
- Records
- 31
- Recruiting
- 3
- Recruiting sites
- 774
- Countries
- 34
- Records
- 15
- Recruiting
- 3
- Recruiting sites
- 3
- Countries
- 1
- Records
- 34
- Recruiting
- 2
- Recruiting sites
- 450
- Countries
- 27
- Records
- 9
- Recruiting
- 2
- Recruiting sites
- 4
- Countries
- 3
- Records
- 9
- Recruiting
- 1
- Recruiting sites
- 8
- Countries
- 1
- Records
- 5
- Recruiting
- 0
- Recruiting sites
- 0
- Countries
- 0
Official registry finder
Filter the exact records.
Search names, former codes, NCT IDs, sponsors, interventions, conditions, cities, and postal codes. Filtered URLs are shareable but intentionally excluded from search indexing so this page remains the canonical source.
52matching registry records
Snapshot timestampJuly 24, 2026 at 9:00 AM UTC
| Program and record | Status | Phase and enrollment | Locations | Primary completion | Registry update | Source |
|---|---|---|---|---|---|---|
| A Study on How NNC0174-1213 Works in People With Overweight or Obesity.NCT06719011 / Novo Nordisk A/S | RecruitingVerified 2025-05 | Phase 1177 estimated | 2 recruiting2 listed / 1 countries | Mar 26, 2026estimated | May 25, 2025ClinicalTrials.gov | Open NCT06719011 ↗ |
| The Role of the Amylin Analogue Cagrilintide in Bone MetabolismNCT07010432 / RAMBO / Novo Nordisk A/S | RecruitingVerified 2025-07 | Phase 1144 estimated | 1 recruiting1 listed / 1 countries | May 3, 2028estimated | Jul 25, 2025ClinicalTrials.gov | Open NCT07010432 ↗ |
| A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to DietNCT07184086 / Novo Nordisk A/S | RecruitingVerified 2025-10 | Phase 180 estimated | 2 recruiting2 listed / 1 countries | Oct 12, 2027estimated | Oct 8, 2025ClinicalTrials.gov | Open NCT07184086 ↗ |
| A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightNCT07253285 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 3460 estimated | 16 recruiting120 listed / 26 countries | Mar 20, 2030estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07253285 ↗ |
| A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or ObeseNCT07411560 / Novo Nordisk A/S | RecruitingVerified 2026-04 | Phase 1100 estimated | 1 recruiting1 listed / 1 countries | Jan 26, 2027estimated | Apr 13, 2026ClinicalTrials.gov | Open NCT07411560 ↗ |
| Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)NCT07527195 / RASMUS / Novo Nordisk A/S | RecruitingVerified 2026-05 | Phase 1100 estimated | 1 recruiting1 listed / 1 countries | Apr 28, 2028estimated | May 7, 2026ClinicalTrials.gov | Open NCT07527195 ↗ |
| A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or ObesityNCT07557953 / Novo Nordisk A/S | RecruitingVerified 2026-05 | Phase 1120 estimated | 1 recruiting1 listed / 1 countries | Apr 13, 2027estimated | May 15, 2026ClinicalTrials.gov | Open NCT07557953 ↗ |
| A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightNCT07564414 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 32,500 estimated | 135 recruiting303 listed / 19 countries | Feb 23, 2028estimated | Jul 8, 2026ClinicalTrials.gov | Open NCT07564414 ↗ |
| A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or ObesityNCT07597018 / Novo Nordisk A/S | RecruitingVerified 2026-06 | Phase 1234 estimated | 1 recruiting1 listed / 1 countries | May 28, 2027estimated | Jun 26, 2026ClinicalTrials.gov | Open NCT07597018 ↗ |
| Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse EventsNCT07607587 / Novo Nordisk A/S | RecruitingVerified 2026-06 | Phase 1114 estimated | 10 recruiting11 listed / 1 countries | Nov 19, 2027estimated | Jun 25, 2026ClinicalTrials.gov | Open NCT07607587 ↗ |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 DiabetesNCT07282613 / REIMAGINEYOUNG / Novo Nordisk A/S | Not yet recruitingVerified 2026-05 | Phase 380 estimated | 0 recruiting56 listed / 10 countries | Sep 7, 2029estimated | May 28, 2026ClinicalTrials.gov | Open NCT07282613 ↗ |
| A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightNCT05567796 / REDEFINE 1 / Novo Nordisk A/S | Active, not recruitingVerified 2026-07 | Phase 33,400 estimated | 0 recruiting256 listed / 23 countries | Oct 30, 2024actual | Jul 17, 2026ClinicalTrials.gov | Open NCT05567796 ↗ |
| REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsNCT05669755 / REDEFINE 3 / Novo Nordisk A/S | Active, not recruitingVerified 2026-07 | Phase 37,101 actual | 0 recruiting633 listed / 25 countries | Sep 1, 2027estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT05669755 ↗ |
| A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With ObesityNCT06780449 / Novo Nordisk A/S | Active, not recruitingVerified 2026-01 | Phase 3400 estimated | 0 recruiting36 listed / 6 countries | Aug 28, 2028estimated | Jan 20, 2026ClinicalTrials.gov | Open NCT06780449 ↗ |
| A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral NeuropathyNCT06797869 / Novo Nordisk A/S | Active, not recruitingVerified 2025-12 | Phase 2142 actual | 0 recruiting54 listed / 7 countries | Aug 21, 2026estimated | Dec 5, 2025ClinicalTrials.gov | Open NCT06797869 ↗ |
| A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-termNCT07011667 / Novo Nordisk A/S | Active, not recruitingVerified 2026-07 | Phase 3609 actual | 0 recruiting46 listed / 1 countries | Mar 1, 2027estimated | Jul 24, 2026ClinicalTrials.gov | Open NCT07011667 ↗ |
| Weight Loss in People Living With Overweight or Obesity Following Treatment With CagrilintideNCT07220642 / RENEW 1 / Novo Nordisk A/S | Active, not recruitingVerified 2026-06 | Phase 3300 estimated | 0 recruiting40 listed / 10 countries | May 11, 2027estimated | Jun 30, 2026ClinicalTrials.gov | Open NCT07220642 ↗ |
| Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With CagrilintideNCT07220759 / RENEW 2 / Novo Nordisk A/S | Active, not recruitingVerified 2026-04 | Phase 3330 estimated | 0 recruiting67 listed / 11 countries | May 12, 2027estimated | Apr 21, 2026ClinicalTrials.gov | Open NCT07220759 ↗ |
| A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body WeightNCT07605052 / Novo Nordisk A/S | Active, not recruitingVerified 2026-07 | Phase 150 estimated | 0 recruiting1 listed / 1 countries | Sep 3, 2026estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT07605052 ↗ |
| Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male SubjectsNCT02300844 / Novo Nordisk A/S | CompletedVerified 2018-01 | Phase 154 actual | 0 recruiting1 listed / 1 countries | Mar 21, 2016actual | Jan 24, 2018ClinicalTrials.gov | Open NCT02300844 ↗ |
| Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or OverweightNCT02958085 / Novo Nordisk A/S | CompletedVerified 2018-01 | Phase 196 actual | 0 recruiting1 listed / 1 countries | Jan 24, 2018actual | Feb 1, 2018ClinicalTrials.gov | Open NCT02958085 ↗ |
| A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or ObeseNCT03600480 / Novo Nordisk A/S | CompletedVerified 2021-11 | Phase 196 actual | 0 recruiting1 listed / 1 countries | Jun 12, 2020actual | Nov 17, 2021ClinicalTrials.gov | Open NCT03600480 ↗ |
| First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.NCT03617081 / Novo Nordisk A/S | CompletedVerified 2020-01 | Phase 140 actual | 0 recruiting1 listed / 1 countries | Dec 13, 2018actual | Jan 10, 2020ClinicalTrials.gov | Open NCT03617081 ↗ |
| A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With ObesityNCT03787225 / Novo Nordisk A/S | CompletedVerified 2019-06 | Phase 166 actual | 0 recruiting1 listed / 1 countries | Jun 4, 2019actual | Jun 24, 2019ClinicalTrials.gov | Open NCT03787225 ↗ |
| Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.NCT03856047 / Novo Nordisk A/S | CompletedVerified 2024-07Registry results posted | Phase 2706 actual | 0 recruiting54 listed / 10 countries | Mar 2, 2020actual | Jul 5, 2024ClinicalTrials.gov | Open NCT03856047 ↗ |
| Research Study to Investigate the Effect of NNC0174-0833 on a Birth Control Pill in Women Who Are Not Able to Become PregnantNCT04074174 / Novo Nordisk A/S | CompletedVerified 2022-01 | Phase 131 actual | 0 recruiting1 listed / 1 countries | Mar 6, 2020actual | Jan 10, 2022ClinicalTrials.gov | Open NCT04074174 ↗ |
| A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney FunctionNCT04209049 / Novo Nordisk A/S | CompletedVerified 2021-01 | Phase 133 actual | 0 recruiting2 listed / 1 countries | Jan 5, 2021actual | Jan 26, 2021ClinicalTrials.gov | Open NCT04209049 ↗ |
| A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or ObesityNCT04940078 / Novo Nordisk A/S | CompletedVerified 2025-12 | Phase 140 actual | 0 recruiting2 listed / 2 countries | Jan 19, 2022actual | Dec 12, 2025ClinicalTrials.gov | Open NCT04940078 ↗ |
| Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 DiabetesNCT04982575 / Novo Nordisk A/S | CompletedVerified 2025-12Registry results posted | Phase 292 actual | 0 recruiting23 listed / 1 countries | Jul 7, 2022actual | Dec 23, 2025ClinicalTrials.gov | Open NCT04982575 ↗ |
| Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)NCT05016882 / Novo Nordisk A/S | CompletedVerified 2025-11 | Phase 2698 actual | 0 recruiting255 listed / 24 countries | Dec 17, 2024actual | Nov 19, 2025ClinicalTrials.gov | Open NCT05016882 ↗ |
| A Research Study of How NNC0174-0833 Behaves in Chinese Volunteers Who Are Normal Weight, Overweight or With ObesityNCT05254158 / Novo Nordisk A/S | CompletedVerified 2023-11 | Phase 124 actual | 0 recruiting1 listed / 1 countries | Sep 7, 2022actual | Nov 7, 2023ClinicalTrials.gov | Open NCT05254158 ↗ |
| A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose WeightNCT05394519 / REDEFINE 2 / Novo Nordisk A/S | CompletedVerified 2026-01 | Phase 31,200 actual | 0 recruiting179 listed / 13 countries | Jan 28, 2025actual | Jan 28, 2026ClinicalTrials.gov | Open NCT05394519 ↗ |
| A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the BodyNCT05564104 / Novo Nordisk A/S | CompletedVerified 2025-12 | Phase 132 actual | 0 recruiting4 listed / 3 countries | Sep 6, 2024actual | Dec 12, 2025ClinicalTrials.gov | Open NCT05564104 ↗ |
| A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy ParticipantsNCT05804162 / Novo Nordisk A/S | CompletedVerified 2024-10 | Phase 1107 actual | 0 recruiting1 listed / 1 countries | Aug 12, 2023actual | Nov 1, 2024ClinicalTrials.gov | Open NCT05804162 ↗ |
| A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose WeightNCT05813925 / Novo Nordisk A/S | CompletedVerified 2026-01 | Phase 3331 actual | 0 recruiting28 listed / 2 countries | Jan 17, 2025actual | Jan 22, 2026ClinicalTrials.gov | Open NCT05813925 ↗ |
| A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose WeightNCT05996848 / REDEFINE 6 / Novo Nordisk A/S | CompletedVerified 2026-01 | Phase 3300 actual | 0 recruiting37 listed / 1 countries | Jan 6, 2025actual | Jan 9, 2026ClinicalTrials.gov | Open NCT05996848 ↗ |
| A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06065540 / REIMAGINE 2 / Novo Nordisk A/S | CompletedVerified 2026-07 | Phase 32,734 actual | 0 recruiting405 listed / 32 countries | Nov 19, 2025actual | Jul 8, 2026ClinicalTrials.gov | Open NCT06065540 ↗ |
| A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and PlaceboNCT06131372 / Novo Nordisk A/S | CompletedVerified 2026-03 | Phase 2626 actual | 0 recruiting128 listed / 13 countries | Sep 24, 2025actual | Apr 1, 2026ClinicalTrials.gov | Open NCT06131372 ↗ |
| A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose WeightNCT06131437 / Novo Nordisk A/S | CompletedVerified 2026-02 | Phase 3809 actual | 0 recruiting46 listed / 1 countries | Dec 8, 2025actual | Feb 6, 2026ClinicalTrials.gov | Open NCT06131437 ↗ |
| A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body WeightNCT06207877 / Novo Nordisk A/S | CompletedVerified 2026-01 | Phase 162 actual | 0 recruiting1 listed / 1 countries | Oct 16, 2024actual | Jan 8, 2026ClinicalTrials.gov | Open NCT06207877 ↗ |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06221969 / Novo Nordisk A/S | CompletedVerified 2026-04 | Phase 31,024 actual | 0 recruiting196 listed / 8 countries | Mar 4, 2026actual | Apr 22, 2026ClinicalTrials.gov | Open NCT06221969 ↗ |
| A Study of How CagriSema Works on Appetite in People With Excess Body WeightNCT06267092 / Novo Nordisk A/S | CompletedVerified 2026-01 | Phase 1164 actual | 0 recruiting1 listed / 1 countries | Apr 7, 2025actual | Jan 8, 2026ClinicalTrials.gov | Open NCT06267092 ↗ |
| A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body WeightNCT06289504 / Novo Nordisk A/S | CompletedVerified 2026-05 | Phase 134 actual | 0 recruiting1 listed / 1 countries | Oct 16, 2024actual | May 19, 2026ClinicalTrials.gov | Open NCT06289504 ↗ |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without MetforminNCT06323161 / REIMAGINE 3 / Novo Nordisk A/S | CompletedVerified 2025-11 | Phase 3274 actual | 0 recruiting53 listed / 6 countries | Sep 9, 2025actual | Nov 28, 2025ClinicalTrials.gov | Open NCT06323161 ↗ |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and ExerciseNCT06323174 / REIMAGINE 1 / Novo Nordisk A/S | CompletedVerified 2026-03 | Phase 3189 actual | 0 recruiting50 listed / 7 countries | Oct 1, 2025actual | Apr 2, 2026ClinicalTrials.gov | Open NCT06323174 ↗ |
| A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose WeightNCT06388187 / Novo Nordisk A/S | CompletedVerified 2026-05 | Phase 3300 actual | 0 recruiting25 listed / 5 countries | Apr 22, 2026actual | May 5, 2026ClinicalTrials.gov | Open NCT06388187 ↗ |
| Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 DiabetesNCT06403761 / Novo Nordisk A/S | CompletedVerified 2026-02 | Phase 1158 actual | 0 recruiting1 listed / 1 countries | Dec 28, 2025actual | Feb 27, 2026ClinicalTrials.gov | Open NCT06403761 ↗ |
| Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver DiseaseNCT06409130 / Novo Nordisk A/S | CompletedVerified 2026-03 | Phase 2270 actual | 0 recruiting102 listed / 14 countries | Nov 21, 2025actual | Mar 12, 2026ClinicalTrials.gov | Open NCT06409130 ↗ |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or BothNCT06534411 / REIMAGINE 5 / Novo Nordisk A/S | CompletedVerified 2026-07 | Phase 31,023 actual | 0 recruiting163 listed / 14 countries | Jun 2, 2026actual | Jul 17, 2026ClinicalTrials.gov | Open NCT06534411 ↗ |
| A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or ObesityNCT06716307 / Novo Nordisk A/S | CompletedVerified 2025-08 | Phase 118 actual | 0 recruiting1 listed / 1 countries | Mar 28, 2025actual | Aug 27, 2025ClinicalTrials.gov | Open NCT06716307 ↗ |
| A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 DiabetesNCT07357740 / Novo Nordisk A/S | WithdrawnVerified 2026-07 | Phase 20 actual | 0 recruiting61 listed / 8 countries | Aug 25, 2027estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT07357740 ↗ |
| A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body WeightNCT07357766 / Novo Nordisk A/S | WithdrawnVerified 2026-07 | Phase 30 actual | 0 recruiting116 listed / 14 countries | Nov 29, 2027estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT07357766 ↗ |
Recruiting location footprint
Country and US state routes.
Counts are site observations across registry records, not unique facilities. The same research center can appear in multiple studies. Open the exact NCT record before treating a location as current.
Clinical trial finder FAQ
Status, location, and enrollment are different fields.
These answers prevent the most common registry-search errors before a reader follows an official source.
Are any Retatrutide clinical trials recruiting?
Yes. This 2026-07-24 snapshot contains 2 Retatrutide registry records with an overall Recruiting status and 450 listed sites individually marked Recruiting. Overall status does not mean every site is open, and neither status establishes eligibility or enrollment. Open the exact NCT record and verify the individual location before contacting a study team.
How do I find a peptide clinical trial near me?
Enter a city or postal code, optionally add a country or US state, and then open the exact ClinicalTrials.gov record. This finder retains location rows individually marked Recruiting but omits facility and personal contact fields. Confirm current recruitment, eligibility, official contact route, and travel requirements on the registry. Peptide Local does not enroll participants.
Does Recruiting mean I can join the trial?
No. Recruiting is a registry status, not an eligibility decision or appointment. A study can be recruiting overall while some listed locations are not yet recruiting, active but closed, completed, suspended, or missing a current site status. The study team applies the protocol's eligibility and consent process.
Are the drugs in this clinical trial finder FDA approved?
A ClinicalTrials.gov record is not FDA approval. The finder covers investigational programs and can also include studies involving components or comparators with separate regulatory histories. Approval must be verified on the exact FDA label or regulator record, not inferred from a phase, sponsor, trial result, or recruiting status.
Why do only some registry records show posted results?
11 of 268 records in this snapshot expose a ClinicalTrials.gov results module. A record without posted registry results can still have a publication or sponsor announcement elsewhere, while a posted module still requires careful interpretation. Results availability is not a quality rank.
How current is the peptide clinical trial data?
The registry data timestamp is July 24, 2026 at 9:00 AM UTC. The refresh workflow searches exact intervention names and aliases, deduplicates by NCT ID, preserves multi-program studies, and stores overall and individual-site status separately. Registry fields can change after that timestamp, so the direct source remains authoritative for enrollment decisions.
Evidence boundary
A registry finder, not an enrollment service.
A dated transformation of ClinicalTrials.gov intervention-search records for thirteen named Peptide Local pipeline programs. Study sponsors or investigators submit and maintain registry records. Overall status, individual-site status, enrollment, locations, completion dates, and results availability can change. Recruiting status does not establish eligibility, enrollment, treatment access, regulatory approval, routine availability, or a favorable benefit-risk conclusion.
Peptide Local omits personal contact details and does not screen participants, recommend a protocol, interpret eligibility, arrange treatment, or authenticate commercial products that reuse an investigational program's name.
Read the official API documentation ↗Understand evidence categories →